-
-
2.发明公开Methods for preparing T-cells for cell therapy 有权Verfahren zur Herstellung von T-Zellen zur Zelltherapie
公开(公告)号：EP2573166A2
公开(公告)日：2013-03-27
申请号：EP12177732.0
申请日：2005-02-24
发明人： Har-Noy, Michael
CPC分类号： C12N5/0636 , A61K2039/5154 , A61K2039/57 , C12N2501/23 , C12N2501/40 , C12N2501/51 , C12N2501/515 , C12N2501/998 , C12N2531/00 , C12N2533/40
摘要： A biodegradable device for activating T-cells, the device comprising:
a biodegradable support wherein the support is non-toxic in humans; and
a first material attached to the biodegradable support wherein the first material is capable of crosslinking second materials, wherein the second material is capable of binding to a T-cell surface antigen.摘要翻译： 一种用于活化T细胞的可生物降解的装置，该装置包括：可生物降解的载体，其中载体在人体中是无毒的; 以及连接到所述可生物降解的载体上的第一材料，其中所述第一材料能够交联第二材料，其中所述第二材料能够结合T细胞表面抗原。
-
公开(公告)号：EP2334309A4
公开(公告)日：2013-01-09
申请号：EP09818495
申请日：2009-10-01
发明人： HAR-NOY MICHAEL
CPC分类号： A61K35/17 , A61K39/0011 , A61K2035/124 , A61K2039/5152 , A61K2039/5158 , A61K2039/545 , A61K2039/57 , C12N5/0636 , C12N2501/23 , C12N2501/51 , C12N2501/515
摘要： The present invention includes vaccine compositions and methods for using these vaccine compositions in active immunotherapy. The vaccine compositions include allogeneic activated Th1 memory cells. The compositions can also include one or more disease-related antigens. The methods include administering the vaccine compositions to provide a Th1 footprint in normal individuals or patients susceptible to disease or having minimal residual disease.
-
公开(公告)号：EP2003978A1
公开(公告)日：2008-12-24
申请号：EP06750196.5
申请日：2006-04-13
发明人： HAR-NOY, Michael
IPC分类号： A01N63/00
CPC分类号： C12N5/0636 , A61K2035/122
摘要： A method for stimulating the immune system in immunocompromised patients in order to treat opportunistic infection. The method involves the infusion of intentionally mismatched allogeneic cells. In order to prevent graft vs. host disease complications, the allogeneic cells can be irradiated prior to infusion.
-
公开(公告)号：EP1627054A1
公开(公告)日：2006-02-22
申请号：EP04751794.1
申请日：2004-05-11
发明人： Har-Noy, Michael
CPC分类号： A61K39/0005 , A61K35/17 , A61K2039/5154 , A61K2039/57 , C12N5/0636 , C12N2501/51 , C12N2501/515 , C12N2531/00 , C12N2533/40
摘要： A method of manipulating allogeneic cells for use in allogeneic cell therapy protocols is described. The method provides a composition of highly activated allogeneic T-cells which are infused into immunocompetent cancer patients to elicit a novel anti-tumor immune mechanism called the “Mirror Effect”. In contrast to current allogeneic cell therapy protocols where T-cells in the graft mediate the beneficial graft vs. tumor (GVT) and detrimental graft vs. host (GVH) effects, the allogeneic cells of the present invention stimulate host T-cells to mediate the “mirror” of these effects. The mirror of the GVT effect is the host vs. tumor (HVT) effect. The “mirror” of the GVH effect is the host vs. graft (HVG) effect. The effectiveness and widespread application of the anti-tumor GVT effect is limited by the severe toxicity of the GVH effect. In the present invention, the anti-tumor HVT effect occurs in conjunction with a non-toxic HVG rejection effect. The highly activated allogeneic cells of the invention can be used to stimulate host immunity in a complete HLA mis-matched setting in patients that have not had a prior bone marrow transplant or received chemotherapy and/or radiation conditioning regimens.
-
公开(公告)号：EP2606125B1
公开(公告)日：2017-11-22
申请号：EP11818884.6
申请日：2011-08-22
发明人： HAR-NOY, Michael
IPC分类号： C12N5/0783 , A61K35/14 , A61K35/17 , A61K39/00
CPC分类号： C12N5/0636 , A61K35/17 , A61K2039/5158 , A61K2039/57 , C12N5/0638 , C12N2501/51 , C12N2501/515
摘要： A novel cell type has been generated that has both Th1 characteristics and cytolytic activity. These Th1/killer cells are CD4+ cells purified from peripheral blood and manipulated to have Th1 characteristics such as production of IFN-gamma combined with cytolytic activity similar to cytotoxic T-cells (CTL). The CTL activity is targeted toward diseased cells, not normal cells. The cytolytic activity of the Th1/killer cells is mediated by Granzyme B-Perforin mechanism and results in apoptotic death of diseased cells. Methods of producing and using these Th1/killer cells include isolating CD4+ cells from peripheral blood, activating the CD4+ T-cells to form Th1/killer cells and administering these Th1/killer cells with the cytolytic activity to a patient wherein the Th1/killer cells are allogeneic to the patient.
-
公开(公告)号：EP2704741A4
公开(公告)日：2014-11-19
申请号：EP12779413
申请日：2012-05-02
发明人： HAR-NOY MICHAEL
CPC分类号： A61K35/17 , A61K38/217 , B65B1/04
摘要： The present invention includes methods for handling live cell compositions in non-nutritive buffer. The cells in the compositions maintain their identity and functional characteristics after being stored in non-nutrititive media up to about 72 hours. The storage method enables the cells to be manufactured at a processing facility and shipped to a point of care site. The invention also includes compositions that have been stored in non-nutritive buffer at storage temperatures while maintaining the functional characteristics.
摘要翻译： 本发明包括在非营养缓冲液中处理活细胞组合物的方法。 组合物中的细胞在高达约72小时内储存在非营养培养基中后保持其身份和功能特征。 存储方法使得能够在处理设备处制造细胞并运送到护理点。 本发明还包括在保存功能特征的同时在储存温度下储存在非营养缓冲液中的组合物。
-
公开(公告)号：EP2003978B1
公开(公告)日：2014-06-11
申请号：EP06750196.5
申请日：2006-04-13
发明人： HAR-NOY, Michael
IPC分类号： A01N63/00
CPC分类号： C12N5/0636 , A61K2035/122
摘要： A method for stimulating the immune system in immunocompromised patients in order to treat opportunistic infection. The method involves the infusion of intentionally mismatched allogeneic cells. In order to prevent graft vs. host disease complications, the allogeneic cells can be irradiated prior to infusion.
-
9.发明公开METHODS AND COMPOSITIONS FOR LIQUIDATION OF TUMORS 有权VERFAHREN UND ZUSAMMENSETZUNGEN ZUR ENTFERNUNG VON TUMOREN
公开(公告)号：EP2512502A4
公开(公告)日：2013-05-08
申请号：EP10842519
申请日：2010-12-15
发明人： HAR-NOY MICHAEL
CPC分类号： A61K39/0011 , A61B18/02 , A61B18/12 , A61B2018/00613 , A61K38/191 , A61K38/193 , A61K38/2013 , A61K38/208 , A61K38/217 , A61K39/00 , A61K2039/5154 , A61K2039/55516 , A61K2039/55522 , A61K2039/55533 , A61K2039/55538 , A61K2039/57
摘要： This invention relates to compositions and methods for immunotherapy of cancer. Specifically, a method of cancer immunotherapy is described which results in the systemic liquidation of both solid and metastatic tumors whereever they reside in the body. The compositions include activated allogeneic Th1 cells that when administered appropriately lead to liquidation of tumors. The method includes administering priming doses of the therapeutic composition, ablation of a selected tumor lesion along with intratumoral injection of the composition and then infusion of the therapeutic composition. These steps enable the systemic liquidation of tumors secondary to immune cell infiltration and leads to immune-mediated tumor eradication.
摘要翻译： 本发明涉及癌症免疫治疗的组合物和方法。 具体地，描述了一种癌症免疫疗法的方法，其导致固体和转移性肿瘤在身体存在的情况下的系统性清除。 组合物包括活化的同种异体Th1细胞，其在施用时适当地导致肿瘤的清除。 该方法包括施用引发剂量的治疗组合物，消融所选择的肿瘤病变以及肿瘤内注射组合物，然后输注治疗组合物。 这些步骤使得免疫细胞浸润继发的肿瘤的系统性清除，并导致免疫介导的肿瘤根除。
-
公开(公告)号：EP2334309A2
公开(公告)日：2011-06-22
申请号：EP09818495.5
申请日：2009-10-01
发明人： HAR-NOY, Michael
CPC分类号： A61K35/17 , A61K39/0011 , A61K2035/124 , A61K2039/5152 , A61K2039/5158 , A61K2039/545 , A61K2039/57 , C12N5/0636 , C12N2501/23 , C12N2501/51 , C12N2501/515
摘要： The present invention includes vaccine compositions and methods for using these vaccine compositions in active immunotherapy. The vaccine compositions include allogeneic activated Th1 memory cells. The compositions can also include one or more disease-related antigens. The methods include administering the vaccine compositions to provide a Th1 footprint in normal individuals or patients susceptible to disease or having minimal residual disease.
-
-
-
-
-
-
-
-
-
搜索结果
42 条记录 (耗时 0.013 秒)
